Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 May 1;209(9):1060-1062.
doi: 10.1164/rccm.202402-0381ED.

Advancing Drug Development in Idiopathic Pulmonary Fibrosis: Tomorrow Is Now

Yet H Khor  1   2   3   4   5 , Christopher J Ryerson  6   7
Affiliations
Editorial

Advancing Drug Development in Idiopathic Pulmonary Fibrosis: Tomorrow Is Now

Yet H Khor et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Addressing challenges of drug discovery and development in idiopathic pulmonary fibrosis. *Data were obtained from clinicaltrials.gov for the trial start and completion dates and PubMed for the online publication dates. †Based on the ZEPHYRUS 2 trial that was initiated after publication of the PRAISE trial. The ZEPHYRUS 1 trial was commenced approximately 8 months before publication of the PRAISE trial. IPF = idiopathic pulmonary fibrosis; RCT = randomized controlled trial.
See this image and copyright information in PMC

Comment on

References

    1. Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature . 2020;587:555–566. - PMC - PubMed
    1. Richeldi L, Schiffman C, Behr J, Inoue Y, Corte TJ, Cottin V, et al. Zinpentraxin alfa for idiopathic pulmonary fibrosis: the randomized phase III STARSCAPE trial. Am J Respir Crit Care Med . 2024;209:1132–1140. - PMC - PubMed
    1. Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA . 2018;319:2299–2307. - PMC - PubMed
    1. Khor YH, Schulte M, Johannson KA, Marcoux V, Fisher JH, Assayag D, et al. Austin ILD Registry and CARE-PF Investigators ALLIANCE Study Group. Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study. Eur Respir J . 2023;61:2202163. - PubMed
    1. U.S. Food and Drug Administration. Table of surrogate endpoints that were the basis of drug approval or licensure. Silver Spring, MD: U.S. Food and Drug Administration; 2023. https://www.fda.gov/drugs/development-resources/table-surrogate-endpoint...

MeSH terms